Kelsey E. Loomis

Associate

Home 9 Person 9 Kelsey E. Loomis
๏ธ
Home 9 Person 9 Kelsey E. Loomis

Kelsey E. Loomis

Associate

Kelsey is an Associate at Wiggin and Dana in the Life Sciences Practice Group. Kelseyโ€™s practice primarily focuses on clinical trial operations, privacy and data protection matters, research and development collaborations, and licensing arrangements. She is also a member of wiggin(x).ย 

Prior to joining Wiggin and Dana, Kelsey was Research and Development Associate Counsel for Alexion Pharmaceuticals, where she provided advice and counsel to the global Research and Development organization on clinical trial matters as well as research programs and collaborations. Kelsey also served as Corporate Counsel at Achillion Pharmaceuticals, where she advised clients on R&D, privacy and healthcare compliance matters.

Kelsey earned her J.D. cum laude from Quinnipiac Law School, with a Health Law concentration in which she graduated with honors. She received her Bachelor of Arts in Government and Economics from Connecticut College.

Education

  • Quinnipiac University School of Law (J.D., 2019)
    • cum laude
  • Connecticut College (B.A., 2013)

Bar Admissions

Awards and Recognitions

Publications

Sorry, No posts.

Events

When: July 25, 2024

Location: Seaport Hotel Boston, MA

People: Patti Kavee Melick , Kate E. Cassidy , Kelsey E. Loomis

When: May 15, 2024

at 8:00am

- 11:00am

Location: Hotel Marcel, New Haven, CT

People: Patti Kavee Melick , Tobias F. Bannon, III , Kelsey E. Loomis , Samantha Scheer

When: March 7, 2024

at 1:30pm

- 4:30pm

Location: The Jackson Laboratory in Farmington, CT, 06032

People: Tobias F. Bannon, III , Patti Kavee Melick , Kelsey E. Loomis

When: March 7, 2023

at 8:30am

- 3:30pm

Location: Yale's Greenberg Center, New Haven, CT

People: Kelsey E. Loomis

Podcasts

Sorry, No posts.

Experience

  • Representedย Rallybio Corporation in its acquisition of worldwide exclusive rights toย Sanofiโ€™sย KY1066 (RLYB331 going forward), a preclinical potentially first-in-class antibody. RLYB331 has the potential to address a significant unmet need for patients with severe anemia with ineffective erythropoiesis and iron overload, such as beta thalassemia (BT) and a subset of myelodysplastic syndromes (MDS), amongst others.

Firm Highlights